← Back to headlines
CSL Signs Licensing Deal with Eli Lilly for Kidney Disease Treatment
CSL has entered into a licensing agreement with Eli Lilly for clazakizumab, a treatment for kidney disease.
17 Feb, 21:26 — 17 Feb, 21:26
ℹOnly 1 source covers this story
